New shingles vaccine trial aims for safer protection in adults 40+
NCT ID NCT07633197
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new shingles vaccine in 120 adults aged 40 and older. The main goal is to check safety and side effects at different doses, while also looking at how well the vaccine triggers an immune response. Participants receive either the vaccine or a placebo, and no one knows which they got.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan CDC
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.